Nuclear Factor-κB Induced by Doxorubicin Is Deficient in Phosphorylation and Acetylation and Represses Nuclear Factor-κB–Dependent Transcription in Cancer Cells
Open accessThe DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.
Abstract
The primary goal of chemotherapy is to cause cancer cell death. However, a side effect of many commonly used chemotherapeutic drugs is the activation of nuclear factor-κB (NF-κB), a potent inducer of antiapoptotic genes, which may blunt the therapeutic efficacy of these compounds. We have assessed the effect of doxorubicin, an anthracycline in widespread clinical use, on NF-κB activation and expression of antiapoptotic genes in breast cancer cells. We show that doxorubicin treatment activates NF-κB signaling and produces NF-κB complexes that are competent for NF-κB binding in vitro. Surprisingly, these NF-κB complexes suppress, rather than activate, constitutive- and cytokine-induced NF-κB–dependent transcription. We show that doxorubicin treatment produces RelA, which is deficient in phosphorylation and acetylation and which blocks NF-κB signaling in a histone deacetylase–independent manner, and we show that NF-κB activated by doxorubicin does not remain stably bound to κB elements in vivo. Together these data show that NF-κB signaling induced by doxorubicin reduces expression of NF-κB–dependent genes in cancer cells.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
NF-κB at the crossroads of life and death
Karin, M., & Lin, A. (2002) · Nature Immunology · doi:10.1038/ni0302-221 · Cited by 2,709
Zhong, H., Voll, R. E., & Ghosh, S. (1998) · Molecular Cell · doi:10.1016/s1097-2765(00)80066-0 · Cited by 1,210
Acetylation of RelA at discrete sites regulates distinct nuclear functions of NF‐κB
Chen, L., Mu, Y., & Greene, W. C. (2002) · The EMBO Journal · doi:10.1093/emboj/cdf660 · Cited by 827 · cited 1×
“However, additional constraints regulate the association of NF-nB with nB sites in vivo , and it is possible that deficits in the post-translational modifications of RelA may reduce its ability to bind or assemble factors necessary for stable DNA association (26, 27).”
A novel ionizing radiation-induced signaling pathway that activates the transcription factor NF-κB
Lee, S.-J., Dimtchev, A., Lavin, M. F., Dritschilo, A., & Jung, M. (1998) · Oncogene · doi:10.1038/sj.onc.1202088 · Cited by 136 · cited 1×
“The precise mechanisms that allow chemotherapeutic drugs to induce NF-nB activation have been slow to emerge, but recent findings indicate that single- or double-stranded DNA breaks produced by chemotherapeutic topoisomerase inhibitors are detected by the ataxia telangiectasia–mutated protein (11, 12), which then init…”
Cited by
Histone deacetylases and cancer
Glozak, M. A., & Seto, E. (2007) · Oncogene · doi:10.1038/sj.onc.1210610 · Cited by 1,031
The diverse and complex roles of NF-κB subunits in cancer
Perkins, N. D. (2012) · Nature Reviews Cancer · doi:10.1038/nrc3204 · Cited by 852
Nuclear factor-κB and inhibitor of κB kinase pathways in oncogenic initiation and progression
Bassères, D. S., & Baldwin, A. S. (2006) · Oncogene · doi:10.1038/sj.onc.1209942 · Cited by 667
Good cop, bad cop: the different faces of NF-κB
Perkins, N. D., & Gilmore, T. D. (2006) · Cell Death & Differentiation · doi:10.1038/sj.cdd.4401838 · Cited by 489
Current insights into the regulation of programmed cell death by NF-κB
Dutta, J., Fan, Y., Gupta, N., Fan, G., & Gélinas, C. (2006) · Oncogene · doi:10.1038/sj.onc.1209938 · Cited by 407
Metadata
- Authors
- Ho, W. C., Dickson, K. M., & Barker, P. A.
- Venue
- Cancer Research
- Published
- 2005-05-15
- Volume
- 65
- Issue
- 10
- Pages
- 4273-4281
- ISSN
- 0008-5472 (ISSN-L)
- 1538-7445
- OpenAlex
- W2146893766
- Cited by
- 92
- References
- 4
- FWCI
- 3.09
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Nuclear Factor-κB Induced by Doxorubicin Is Deficient in Phosphorylation and Acetylation and Represses Nuclear Factor-κB–Dependent Transcription in Cancer Cells. https://app.cochat.ai/papers/10.1158/0008-5472.can-04-3494
- The paper
- Ho, W. C., Dickson, K. M., & Barker, P. A. (2005). Nuclear Factor-κB Induced by Doxorubicin Is Deficient in Phosphorylation and Acetylation and Represses Nuclear Factor-κB–Dependent Transcription in Cancer Cells. Cancer Research. https://doi.org/10.1158/0008-5472.can-04-3494
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.